The information in this prospectus is not complete and may be changed. The Selling
Securityholders may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these
securities in any jurisdiction where the offer or sale is not permitted.
Subject to completion, dated July 19, 2024
PRELIMINARY PROSPECTUS
Lanvin Group
Holdings Limited
Primary Offering of
31,979,969 Ordinary Shares Underlying Warrants
Secondary Offering of
133,460,241 Ordinary Shares
11,280,000 Warrants to Purchase Ordinary Shares
This prospectus relates to the offer and sale by us of (i) up to 20,699,969 of our ordinary shares, par value $0.000001 per share
(Ordinary Shares) that are issuable by us upon the exercise of 20,699,969 Public Warrants (as defined below) that were previously registered and (ii) up to 11,280,000 Ordinary Shares that are issuable by us upon the exercise of
11,280,000 Private Placement Warrants (as defined below).
This prospectus also relates to the offer and sale from time to time by the
selling securityholders named in this prospectus (collectively, the Selling Securityholders) of (A) up to 133,460,241 Ordinary Shares, consisting of (i) up to 15,327,225 Ordinary Shares that were issued on a private placement
basis at a price of $10.00 per share to the PIPE Investors (as defined below) in connection with our Business Combination (as defined below) pursuant to their subscription agreements (PIPE Shares), (ii) up to 4,500,000 Ordinary Shares
that were issued to Aspex Master Fund (Aspex) pursuant to its forward purchase agreement, which are comprised of (a) 4,000,000 Ordinary Shares issued in exchange for the 4,000,000 Class A ordinary shares of Primavera Capital
Acquisition Corporation (PCAC) that were issued to Aspex by PCAC on a private placement basis at a price of $10.00 per share (assuming no value is assigned to Private Placement Warrants originally issued to Aspex referred to in clause
(B) below), and (b) 500,000 Ordinary Shares issued in exchange for the 500,000 Class B ordinary shares of PCAC, or founder shares, that were transferred to Aspex by Primavera Capital Acquisition LLC (the Sponsor) on a private
placement basis for no consideration, (iii) up to 97,353,016 Ordinary Shares that were issued to certain other shareholders of FFG (FFG Selling Securityholders) in exchange for the 362,577,510 FFG ordinary shares issued to FFG
Selling Securityholders by FFG on a private placement basis at a weighted average price of $1.41 per share (calculated based on the applicable exchange rate at the time of the investments, or an effective price of $5.24 per share, as adjusted for
the Exchange Ratio) pursuant to their subscription agreements, (iv) up to 5,000,000 Ordinary Shares that were issued to the Sponsor in exchange for the 5,000,000 Class B ordinary shares of PCAC issued to the Sponsor by PCAC at an effective
price of $0.005 per share, as further described in the immediately following paragraph, and (v) up to 11,280,000 Ordinary Shares issuable upon the exercise of Private Placement Warrants and (B) up to 11,280,000 Warrants originally issued
on a private placement basis, each exercisable for one Ordinary Share at an exercise price of $11.50 per share (Private Placement Warrants), which are comprised of (i) up to 1,000,000 Private Placement Warrants that were originally
issued to Aspex pursuant to its forward purchase agreement and (ii) up to 10,280,000 Private Placement Warrants that were originally issued to the Sponsor at a price of $1.00 per warrant in connection with PCACs initial public offering.
The Sponsor paid $25,000, or approximately $0.002 per share, to cover certain of offering and formation costs of PCAC in exchange for
12,350,000 founder shares (after giving effect to all rounds of share recapitalization). The Sponsor transferred (i) an aggregate of 335,625 founder shares to PCACs independent directors for an aggregate purchase price of $985, or
approximately $0.003 per share, and (ii) an aggregate of 1,000,000 founder shares to Aspex and Sky Venture Partners L.P. (Sky Venture) pursuant to their forward purchase agreements for no consideration. After giving effect to such
transfers, the Sponsor held 11,014,375 founder shares immediately prior to the consummation of PCACs initial public offering. Immediately prior to the consummation of our Business Combination, the Sponsor surrendered 6,014,375 founder shares
to PCAC for no consideration pursuant to a letter agreement entered into in December 2022, following which the number of founder shares held by the Sponsor was reduced to 5,000,000. We issued 5,000,000 Ordinary Shares in exchange for the 5,000,000
founder shares held by the Sponsor. This resulted in an effective price of approximately $0.005 per share for the Ordinary Shares received by the Sponsor and being registered for resale by the Sponsor pursuant to this registration statement.